3 August 2026

Invitation to comment on the commercial supply
of a genetically modified multivalent vaccine for chickens (DIR 224)

The Gene Technology Regulator is assessing an application from Intervet Australia Pty Ltd for the commercial supply of a genetically modified (GM) multivalent vaccine to protect chickens against Marek’s disease, Newcastle disease and infectious laryngotracheitis.

The vaccine must also be registered by the Australian Pesticides and Veterinary Medicines Authority (APVMA) before it is approved for use in Australia.

The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and welcomes written submissions relating to the protection of human health and safety and the environment prior to making a decision on whether to issue the licence. The consultation RARMP and related information can be obtained via the consultation hub at https://consultations.health.gov.au/ogtr/dir-224-consultation, or from the contacts below. Submissions should reference DIR 224 and be received by 25 September 2026.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601

Telephone: 1800 181 030   Website: www.ogtr.gov.au

E-mail: ogtr@health.gov.au